Dr. Oz’s Response to Joy Behar’s TrumpRx Critique
On a recent episode of “The View,” Joy Behar expressed her strong concerns regarding a new prescription drug initiative associated with former President Donald Trump. She warned dramatically that if Trump’s name were on a prescription, “we’re all going to die.” This heated exchange triggered a backlash from Dr. Mehmet Oz, the administrator of the Centers for Medicare and Medicaid Services.
In a light-hearted yet pointed jab on social media, Oz remarked, “Unfortunately, TrumpRx.gov does not yet have a treatment for Trump Derangement Syndrome, but we are working on it.” His comment struck a chord with those following the debate.
The disagreement intensified as Behar questioned the credibility of the TrumpRx program during her segment. She noted that Trump’s past ventures, which often ended poorly, fueled her distrust. “If Trump puts his name on a prescription, we’re all going to die, right?” she stated, referring to Trump’s previous business failures like Trump Shuttle and Trump University.
Amid the discussion, Alyssa Farrar Griffin countered Behar’s concerns by clarifying that the site featured existing prescription drugs rather than new ones branded by Trump. “The drug doesn’t actually have his name on it,” she mentioned, adding that the affordability of medications should outweigh political affiliations.
Sunny Hostin sided with Behar, implying that Trump’s motivations were less than genuine. She underscored Hostin’s skepticism, especially after Trump joked about wanting to make people “better” while also ensuring they stayed “wealthy.”
Sarah Haines brought attention back to the main issue—the affordability of medications—arguing that the name attached to the initiative was less important than its actual impact. “If you’re going to lower the price and get results with this, call it ‘Donald Trump’s drug,’” she asserted.
The debate further heated when Behar and Hostin accused Griffin and Haines of being overly naive. Ultimately, Whoopi Goldberg suggested that viewers should assess the program for themselves, emphasizing, “Let’s see how it works, and if it works for you, please do it.”
The White House has described TrumpRx as a central platform aimed at helping patients compare cash prices of medications with insurance options. They indicated that the site would focus on commonly used drugs, excluding controlled substances and those with specific risk assessments.
“The View” has not yet commented on the ongoing discussions surrounding the TrumpRx initiative.
